Evidence map›Paper›PMID 42291272›Full record

ArticleiScience2026

A multi-center clinical evaluation on first-in-class ROP-based IGRA for tuberculosis diagnosis.

Qiang Li, Yulin Huang, Lihui Nie, Mengqiu Gao, Ruimei Zhang, Jiawei Yan, Hongyan Jia, Maoying Fu, Aolin He, Qiping Ge and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Qiang LiDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Yulin HuangDepartment of Epidemiology and Clinical Research Methodology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Lihui NieDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Mengqiu GaoDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Ruimei ZhangDepartment of Tuberculosis, Xuzhou Infectious Diseases Hospital, Xuzhou, China.
Jiawei YanClinical Laboratory, Xuzhou Infectious Diseases Hospital, Xuzhou, China.
Hongyan JiaBeijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Maoying FuDepartment of Infectious Diseases, The First People's Hospital of Kunshan, Suzhou, China.
Aolin HeClinical Research Center, The First People's Hospital of Kunshan, Suzhou, China.
Qiping GeDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Hua LiDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Yanhua SongDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Yu PangDepartment of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Liping PanBeijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Shisong JiangDepartment of Oncology, University of Oxford, Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) remains a leading global cause of death from infectious disease. Current enzyme-linked immunospot assay (ELISPOT)-based interferon-gamma release assays (IGRAs) rely on pooled synthetic peptides, which pose challenges for large-scale good manufacturing practice (GMP) production and quality control. To address these limitations, we developed recombinant overlapping peptide (ROP) technology and evaluated its diagnostic performance in a multi-center clinical trial in China (September 2021-August 2022). Two reagents, representing distinct antigen presentation pathways, demonstrated high concordance. ROP-TB showed excellent agreement with T-SPOT.TB, yielding positive, negative, and overall agreement rates of 95.29%, 93.51%, and 94.49%, respectively (κ = 0.889,

Indexed as

Health sciencesMedicineRespiratory medicine

Identifiers

PMID42291272
PMCPMC13260212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.